Clinical TrialMay 30, 2026, 08:02 AM
Immatics IMA203CD8 Shows 63% ORR in Gynecologic Cancers
AI Summary
Immatics N.V. announced updated positive Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at ASCO 2026. The therapy demonstrated significant anti-tumor activity, with a 63% objective response rate (ORR) and 50% confirmed ORR (cORR) in platinum-resistant ovarian and uterine cancer, including four complete responses. In synovial sarcoma, IMA203CD8 achieved a 67% ORR and 64% cORR, with responses lasting up to approximately three years. The treatment exhibited a manageable and consistent tolerability profile across all patient populations, supporting its continued development in PRAME-positive solid tumors.
Key Highlights
- IMA203CD8 achieved 63% ORR and 50% cORR in platinum-resistant ovarian and uterine cancer, including 4 complete responses.
- Longest ongoing response in gynecologic cancers was 12 months post-infusion.
- IMA203CD8 showed 67% ORR and 64% cORR in heavily pretreated synovial sarcoma patients, with 1 complete response.
- Responses in synovial sarcoma were ongoing for up to ~3 years.
- Manageable and consistent tolerability profile observed across all patient populations.
- Determination of recommended Phase 2 dose (RP2D) remains expected in 2026.
- Data presented at ASCO 2026 for gynecologic cancers (Abstract ID 5509) and synovial sarcoma (Abstract ID 11516).
Price Impact
More from IMTX